We are building a developmental pipeline targeting cardiovascular disease using three or more cardiac effector genes and employing several therapeutic delivery modalities. Our team is focused on completing the current Phase I study for our lead clinical candidate while moving additional candidates through discovery.
Lead Clinical Candidate
Triple-Gene’s lead investigational therapy INXN-4001 for heart failure is being evaluated in Phase I open label study in adult patients with implanted Left Ventricular Assist Device (LVAD). INXN-4001 uses non-viral delivery of a constitutively expressed multigenic plasmid designed to express human S100A1, SDF-1α, and VEGF165, gene products which affect progenitor cell recruitment, angiogenesis, and calcium handling, respectively. The investigational plasmid therapy is designed to target the underlying molecular mechanisms of pathological myocardial remodeling. It is delivered via Retrograde Coronary Sinus Infusion (RCSI) which allows for cardiac-specific delivery to the ventricle.
INXN-4001 is being evaluated in a Phase I open label study in adult patients with implanted Left Ventricular Assist Device (LVAD). The study is designed to investigate the safety of supplemental cardiac expression of S100A1, SDF-1α and VEGF-165 from a single, multigenic plasmid delivered via Retrograde Coronary Sinus Infusion (RCSI) in stable patients implanted with a LVAD for mechanical support of end stage heart failure, either as a bridge to transplant or destination therapy. (Clinical trial identifier: NCT03409627)